2019-2021
—CONTEXT
CARETAKER TOOL KIT : OBJECTIVE SENSE MAKING TOOLS CONSERVATION

DEPROGRAMMING AS DECOLONIALISM





We are witnessing the single largest wealth transfer in history 1

Wall Street exploited disaster capitalism 2 against Main Street. 

BlackRock and Vanguard form a secret monopoly that has a near total control of the global market. In all, they have ownership in 1,600 American firms, which in 2015 had combined revenues of $9.1 trillion 3.

When you add in the third-largest global owner, State Street, their combined ownership encompasses nearly 90% of all S&P 500 firms.
 
A Bloomberg report states that both these companies in the year 2028, together will have investments in the amount of 20 trillion dollars. That means that they will own almost everything. 

“MONOPOLY”
Vanguard is the largest shareholder of BlackRock.

Vanguard itself, on the other hand, has a unique structure that makes its ownership more difficult to discern, but many of the oldest, richest families in the world can be linked to Vanguard funds. 

“BIG PHARMA”
In February 2020, BlackRock and Vanguard were the two largest shareholders of GlaxoSmithKline, at 7% and 3.5% of shares respectively.

At Pfizer, the ownership is reversed, with Vanguard being the top investor and BlackRock the second-largest stockholder. 

“ESTABLISHMENT MEDIA”
When it comes to The New York Times, as of May 2021, BlackRock is the second-largest stockholder at 7.43% of total shares, just after The Vanguard Group, which owns the largest portion (8.11%).

The bottom line is that BlackRock and Vanguard, individually and combined, own enough shares at any given time that we can say they easily control both Big Pharma and the centralized legacy media — and then some.

WHAT ARE THE IMPLICATIONS FOR MISUSE OF THIS MONOPOLY POWER DURING A HEALTH GLOBAL CRISIS, SUCH AS THE COVID-19 PANDEMIC?

FDA EUA, PAGE 3 SECION 111 (CRITERIA) NOTATION 4

Based on this declaration and determination, FDA may issue an EUA after FDA has determined that the following statutory requirements are met (section 564 of the FD&C Act (21 U.S.C. 360bbb-3)) (Ref. 3):

• There is no adequate, approved, and available alternative to the product for diagnosing, preventing, or treating the disease or condition.

F